Edwards Lifesciences Corporation $EW Shares Sold by Huntington National Bank

Huntington National Bank cut its position in Edwards Lifesciences Corporation (NYSE:EW) by 4.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 165,406 shares of the medical research company’s stock after selling 8,527 shares during the quarter. Huntington National Bank’s holdings in Edwards Lifesciences were worth $12,936,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of EW. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at $26,000. SouthState Corp acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at $27,000. Rosenberg Matthew Hamilton acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at $28,000. Costello Asset Management INC acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at $29,000. Finally, Riverview Trust Co grew its stake in shares of Edwards Lifesciences by 44.5% in the second quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock valued at $40,000 after buying an additional 159 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Oppenheimer cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Barclays reissued an “overweight” rating and set a $99.00 target price (up from $95.00) on shares of Edwards Lifesciences in a research note on Friday. Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Stifel Nicolaus boosted their target price on Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, Mizuho boosted their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Trading Up 1.3%

NYSE:EW opened at $84.13 on Wednesday. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $87.09. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market cap of $49.39 billion, a P/E ratio of 12.11, a P/E/G ratio of 3.97 and a beta of 1.05. The stock has a 50-day simple moving average of $77.68 and a 200-day simple moving average of $77.14.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business’s revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.